Bayer sells a minority stake in its contraceptives business to Apollo for €3 billion https://t.co/bsOPX303fH ...

In today’s Markets Daily India, we look at RBI’s delicate balancing act, the earnings outlook for pharma, and why gold has stabilized. https://t.co/cYWdMkHtqF ...

Base investing is booming just weeks after SpaceX's record IPO. Bloomberg reports in the private markets, Jeff Bezos' Blue Origin is seeking outside capital for the first time at a roughly $130,000,000,000 valuation. Venture investors are also pouring billions into companies betting on the orbital economy, but there's one big bottleneck, launch capacity.Access has been limited. Costs have been rising, and getting to space is still hard. Joining us now is Delian Asparouhov, partner of Founders Fund chairman ...

But pills that cost cents to produce still sell for $25 https://t.co/f0XeeSG9a4 ...

After the former Pfizer headquarters faced the risk of partial collapse, developers expect costlier safety reviews and insurance https://t.co/QcvqVG40oP ...

While blockbuster GLP-1 drugs like Wegovy and Zepbound are known for helping people lose weight, a new wave of people are using them to treat their eating disorders instead. Success, for them, might actually involve gaining weight. https://t.co/QaxOhACu6o ...

AstraZeneca shares fall after its drug Wainua failed to reduce deaths in a heart condition trial https://t.co/VmYHQYz6mV ...

UK homebuyer enquiries weak, AstraZeneca drug fails, and where to watch England versus Norway -- get briefed ahead of your morning calls with The London Rush https://t.co/xTkDkzBWNB ...

The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo. https://t.co/HYqVtucW2Z ...